tirzepatide vs semaglutide weight loss comparison caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide tirzepatide vs semaglutide weight loss

The other study looked at 660 overweight people who had a weight-related disease other than diabetes

According to a research brief published in the August issue of the Journal of Managed Care and Specialty Pharmacy , roughly one in three (32%) patients were still on their medication after a year

British Journal of Pharmacology, 173 (11), 18201834

Patients living with obesity and PCOS often present significant visceral fat accumulation, resulting in elevated free fatty acid release that contributes to increased hepatic total cholesterol synthesis and dyslipidemia, manifesting as elevated triglyceride, total cholesterol, and LDL-C levels

Related products Sale